Tranexamic acid (TXA) is an antifibrinolytic agent commonly used for the treatment or
prevention of bleeding. Indications for TXA are diverse, including heavy menstrual bleeding …

OBJECTIVE Tranexamic acid is a cost-effective intervention for the prevention of postpartum
hemorrhage among women who undergo cesarean delivery, but the evidence to support its …

Background Every 2 minutes, there is a pregnancy-related death worldwide, with one-third
caused by severe postpartum hemorrhage. Although international trials demonstrated the …

Background Post-partum haemorrhage (PPH) is a leading cause of maternal death
worldwide. The WOMAN trial assessed the effects of tranexamic acid (TXA) on death and …

Antifibrinolytic agents such as tranexamic acid (TXA) inhibit the fibrinolytic pathway and
protect blood clots from being degraded, thereby promoting hemostasis. They have been …

Tranexamic acid reduces bleeding by inhibiting the breakdown of blood clots. It is cost-
effective and heat-stable with a long shelf life. In the WOMAN trial, tranexamic acid reduced …

Tranexamic acid (TXA) effectively reduces bleeding in women with postpartum hemorrhage
(PPH) in hospital settings. To guide policies and practices, this rapid scoping review …

In the last decades, tranexamic acid (TXA) has emerged as an essential tool in blood loss
management in obstetrics. TXA prophylaxis for postpartum haemorrhage (PPH) has been …

The exclusion of pregnant populations, women of reproductive age, and the fetus from
clinical trials of therapeutics is a major global public health issue. It is also a problem of …

We conducted a narrative review in six areas of obstetric emergencies: category‐1
caesarean section; difficult and failed airway; massive obstetric haemorrhage; hypertensive …